IMA

ImageneBio, Inc. (IMA) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report covers the period ended March 31, 2026. ImageneBio, Inc. (formerly Ikena Oncology, Inc.) is a clinical-stage biopharmaceutical company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody for immunological and inflammatory diseases, specifically atopic dermatitis (AD) and alopecia areata (AA). The company completed a reverse recapitalization merger with Legacy Inmagene on July 25, 2025, and divested all non-IMG-007 assets (the "Non-OX40 Divestiture") to a related party, Miragene Inc., leaving IMG-007 as its sole product candidate.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: License revenue dropped to zero in Q1 2026 compared to $0.8 million in Q1 2025. This is due to the divestiture of non-IMG-007 programs in July 2025, which previously generated license income.
• Increased Operating Expenses: Total operating expenses increased by $5.3 million (78%) year-over-year.
  • R&D Expenses: Rose $1.9 million to $6.0 million, driven by increased clinical trial costs for the Phase 2b AD study.
  • G&A Expenses: Rose $3.4 million to $6.1 million, primarily due to increased personnel costs (including retention/severance), stock-based compensation ($0.7 million), and public company compliance costs.
• Liquidity Position: Cash and marketable securities increased significantly to $117.2 million as of March 31, 2026, compared to $4.9 million in Q1 2025. This reflects the capital raised via the 2025 PIPE financing ($75.0 million) and the reverse merger assets.
• Other Income: Interest income increased to $1.1 million in Q1 2026 due to higher invested cash balances, compared to a net interest expense of $0.1 million in Q1 2025.

Guidance, Outlook, and Risks

• Clinical Outlook:
  • Atopic Dermatitis (AD): A multi-country Phase 2b dose-finding study is ongoing. Topline data is expected in Q4 2027.
  • Alopecia Areata (AA): The company expects to initiate a Phase 2 study by the end of 2026, with initial data expected in 2028.
• Capital Resources: Management believes existing cash, cash equivalents, and marketable securities ($117.2 million) plus $30.0 million in proceeds from a private placement of pre-funded warrants closed in April 2026, are sufficient to fund operations through at least the next 12 months.
• Material Weakness in Internal Controls: The company identified a material weakness in internal control over financial reporting related to a lack of segregation of duties regarding journal entries and account reconciliations. This weakness was not remediated as of March 31, 2026.
• Key Risks:
  • Single Product Dependence: The business is entirely dependent on the success of IMG-007.
  • Manufacturing & Supply Chain: Reliance on a single-source supplier in China (WuXi Biologics) for API and drug product, exposing the company to geopolitical risks, tariffs, and the U.S. BIOSECURE Act.
  • Intellectual Property: Rights to IMG-007 are licensed from Hutchmed; failure to meet diligence obligations could result in termination.

Investor Verification Checklist

• Verify the status and timeline of the Phase 2b AD study and the planned initiation of the Phase 2 AA study.
• Confirm the progress of remediation efforts regarding the material weakness in internal controls over financial reporting.
• Assess the impact of the BIOSECURE Act and U.S.-China trade tensions on the supply chain for IMG-007 manufactured by WuXi Biologics.
• Review the terms of the April 2026 private placement ($30.0 million) and the dilution impact of the pre-funded warrants.
• Monitor the cash burn rate given the increased operating expenses and the timeline to potential revenue generation.